Momenta Phama's (MNTA) Q2 Loss Narrower than Expected

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to Momenta Phama's (MNTA) Q2 Loss Narrower than Expected

Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results

August 4, 2016 8:03 AM EDT

CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the second quarter ended June 30, 2016.

For the second quarter of 2016, the Company reported total revenues of $26.4 million, including $20.7 million in product revenues from Sandozs sale of Glatopa® (glatiramer acetate injection). Momenta reported a net loss of $(21.0) million, or $(0.31) per share for the second quarter compared to a net loss of $(2.2) million, or $(0.04) per share for the same period in 2015. At June 30, 2016, the Company had cash, cash equivalents, and marketable securities of $336.9... More